Table 3. Clinical Results.
| Placebo + Placebo (n=4) |
Omeprazole + Bethanacol (n=6) |
Omeprazole + Placebo (n=4) |
Bethanacol + Placebo (n=5) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Open | Pre | Post | Open | Pre | Post | Open | Pre | Post | Open | |
| GER Episodes/Day | 2.0 (1.6-3.0) | 3.1 (2.3-3.4) | 0.2 (0.1-0.7) | 2.3 (0.6-6.7) | 0.2* (0-2.6) | 0.2 (0-1.0) | 4.9 (4.2-5.0) | 1.7 (0-3.9) | 0.5 (0.2-0.9) | 1.0 (0.8-10) | 2.0 (1.0-10.3) | 1.4 (0.2-8.5) |
| Coughing Episodes/Day | 2.9 (2.0-5.1) | 3.4 (2.5-4.9) | 1.0 (0.5-2.0) | 3.4 (1.0-6.0) | 0.4* (0-3.1) | 1.0 (0.3-1.9) | 5.6 (3.6-8.3) | 2.4 (0.5-6.6) | 0.9 (2.9-6.7) | 5.0 (4.5-8.9) | 3.0 (1.0-7.8) | 4.3 (1.0-6.6) |
| Respiratory Score (0-12) | 2.5 (2.0-4.0) | 3.0 (2.0-3.5) | 0 (0-1.0) | 3.0 (2.0-3.0) | 1.5* (0-2.0) | 0 (0-1.0) | 4.0 (3.0-5.0) | 1.5 (0.5-3.0) | 1.5 (0-4.0) | 2.0 (2.0-5.3) | 1.0 (1.0-2.5) | 1.0 (0-2.3) |
| Wheezing Episodes/Day | 1.6 (0.7-3.4) | 1.9 (0.1-4.6) | 0.5 (0-2.4) | 2.3 (0-7.5) | 0.9 (0.1-2.9) | 0.6 (0.1-1.6) | 0.9 (0.3-2.7) | 0.2 (0.7-0.4) | 0.4 (0.1-2.0) | 1.4 (0.3-3.3) | 0 (0-2.5) | 0 (0-1.7) |
| Coughing Episodes/Night | 0.6 (0.5-0.9) | 0.4 (0.4-0.6) | 0.2 (0.1-0.4) | 1.1 (0.4-2.4) | 1.1 (0.1-2.0) | 0.3 (0-1.0) | 1.3 (1.1-3.9) | 0.9 (0-2.4) | 0.1 (0-0.4) | 1.5 (0.5-2.9) | 0.1 (0-1.8) | 0 (0-0.6) |
*P=0.028 after Wilcoxin signed rank analysis of pre vs. post values.